What is HC Wainwright’s Forecast for MetaVia Q1 Earnings?

MetaVia Inc. (NASDAQ:MTVA) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of MetaVia in a note issued to investors on Thursday, September 4th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share. HC Wainwright also issued estimates for MetaVia’s Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.20) EPS and Q4 2026 earnings at ($0.22) EPS.

Separately, Maxim Group dropped their target price on shares of MetaVia from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, May 19th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $7.50.

MetaVia Trading Up 0.4%

NASDAQ MTVA opened at $0.69 on Friday. The company’s 50 day simple moving average is $0.65 and its 200 day simple moving average is $0.93. MetaVia has a 12 month low of $0.56 and a 12 month high of $4.32.

MetaVia (NASDAQ:MTVA) last released its earnings results on Thursday, August 7th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.06.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.